D
Daniel Baumhoer
Researcher at University Hospital of Basel
Publications - 194
Citations - 7608
Daniel Baumhoer is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Medicine & Sarcoma. The author has an hindex of 38, co-authored 157 publications receiving 5571 citations. Previous affiliations of Daniel Baumhoer include University of Basel.
Papers
More filters
Journal ArticleDOI
The landscape of genomic alterations across childhood cancers
Susanne Gröbner,Barbara C. Worst,Joachim Weischenfeldt,Joachim Weischenfeldt,Ivo Buchhalter,Kortine Kleinheinz,Vasilisa A. Rudneva,Pascal Johann,Gnana Prakash Balasubramanian,Maia Segura-Wang,Sebastian Brabetz,Sebastian Bender,Barbara Hutter,Dominik Sturm,Elke Pfaff,Daniel Hübschmann,Gideon Zipprich,Michael Heinold,Michael Heinold,Jürgen Eils,Christian Lawerenz,Serap Erkek,Sander Lambo,Sebastian M. Waszak,Claudia Blattmann,Arndt Borkhardt,Arndt Borkhardt,Michaela Kuhlen,Michaela Kuhlen,Angelika Eggert,Angelika Eggert,Simone Fulda,Manfred Gessler,Jenny Wegert,Roland Kappler,Roland Kappler,Daniel Baumhoer,Stefan Burdach,Stefan Burdach,Renate Kirschner-Schwabe,Renate Kirschner-Schwabe,Udo Kontny,Andreas E. Kulozik,Andreas E. Kulozik,Dietmar R. Lohmann,Simone Hettmer,Cornelia Eckert,Cornelia Eckert,Stefan S. Bielack,Michaela Nathrath,Michaela Nathrath,Charlotte M. Niemeyer,Charlotte M. Niemeyer,Gunther Richter,Gunther Richter,Johannes H. Schulte,Johannes H. Schulte,Reiner Siebert,Frank Westermann,Jan J. Molenaar,Gilles Vassal,Hendrik Witt,Peter Lichter,Ursula Weber,Roland Eils,Roland Eils,Andrey Korshunov,Olaf Witt,Stefan Pfister,Guido Reifenberger,J Felsberg,Christof von Kalle,Manfred Schmidt,Cynthia Bartholomä,Michael Taylor,David T. W. Jones,Natalie Jäger,Korbel Jo,Adrian M. Stütz,Tobias Rausch,Bernhard Radlwimmer,Marie-Laure Yaspo,Hans Lehrach,Hans-Jörg Warnatz,Pablo Landgraf,Benedikt Brors,Marc Zapatka,Marc Zapatka,Susanne Wagner,Susanne Wagner,Andrea Haake,Julia Richter,Gesine Richter,Gesine Richter,Chris Lawerenz,Jules Kerssemakers,Christina Jaeger-Schmidt,Ingrid Scholz,Anke K. Bergmann,Christoph Borst,Birgit Burkhardt,Alexander Claviez,Martin Dreyling,Martin Dreyling,Sonja Eberth,Hermann Einsele,Norbert Frickhofen,Siegfried Haas,Martin-Leo Hansmann,Dennis Karsch,Michael Kneba,Jasmin Lisfeld,Luisa Mantovani-Löffler,Marius Rohde,German Ott,Christina Stadler,Peter Staib,Stephan Stilgenbauer,Lorenz Trümper,Thorsten Zenz,Dieter Kube,Ralf Küppers,Marc A. Weniger,Michael Hummel,Wolfram Klapper,Ulrike Kostezka,Dido Lenze,Peter Möller,Andreas Rosenwald,Monika Szczepanowski,Ole Ammerpohl,Sietse M. Aukema,Vera Binder,Jessica I. Hoell,Ellen Leich,Cristina López,Inga Nagel,Jordan Pischimariov,Philip Rosenstiel,Markus Schilhabel,Stefan Schreiber,Inga Vater,Rabea Wagener,Stephan H. Bernhart,Hans Binder,Gero Doose,Steve Hoffmann,Lydia Hopp,Helene Kretzmer,Markus Kreuz,David Langenberger,Markus Loeffler,Maciej Rosolowski,Matthias Schlesner,Peter F. Stadler,Stephanie Sungalee,Christian P. Kratz,Cornelis M. van Tilburg,Christof M. Kramm,Gudrun Fleischhack,Gudrun Fleischhack,Uta Dirksen,Stefan Rutkowski,Michael C. Frühwald,Katja von Hoff,Stephan Wolf,Thomas Klingebiel,Thomas Klingebiel,Ewa Koscielniak,Jan Koster,Adam C. Resnick,Jinghui Zhang,Yanling Liu,Xin Zhou,Angela J. Waanders,Danny A. Zwijnenburg,Pichai Raman,Ursula D. Weber,Paul A. Northcott,Kristian W. Pajtler,Marcel Kool,Rosario M. Piro,Jan O. Korbel,David T.W. Jones,Lukas Chavez,Stefan M. Pfister +185 more
TL;DR: The data suggest that 7–8% of the children in this cohort carry an unambiguous predisposing germline variant and that nearly 50% of paediatric neoplasms harbour a potentially druggable event, which is highly relevant for the design of future clinical trials.
Journal ArticleDOI
Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.
Sam Behjati,Sam Behjati,Patrick S. Tarpey,Nadege Presneau,Susanne Scheipl,Susanne Scheipl,Nischalan Pillay,Nischalan Pillay,Peter Van Loo,Peter Van Loo,David C. Wedge,Susanna L. Cooke,Gunes Gundem,Helen Davies,Serena Nik-Zainal,Sancha Martin,Stuart McLaren,Victoria Goodie,Ben Robinson,Adam Butler,Jon W. Teague,Dina Halai,Bhavisha Khatri,Ola Myklebost,Daniel Baumhoer,Gernot Jundt,Rifat Hamoudi,Roberto Tirabosco,M Fernanda Amary,P. Andrew Futreal,Michael R. Stratton,Peter J. Campbell,Peter J. Campbell,Adrienne M. Flanagan,Adrienne M. Flanagan +34 more
TL;DR: A remarkable picture of tumor type specificity for histone H 3.3.3 driver alterations emerges, indicating that hist one H3.
Journal ArticleDOI
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan S. Bielack,Sigbjørn Smeland,Jeremy Whelan,Neyssa Marina,Gordana Jovic,Jane Hook,Mark Krailo,Mark C. Gebhardt,Zsuzsanna Papai,James O. Meyer,Helen Nadel,R. Lor Randall,Claudia Deffenbaugh,Rajaram Nagarajan,Bernadette Brennan,G. Douglas Letson,Lisa A. Teot,Allen M. Goorin,Daniel Baumhoer,Leo Kager,Mathias Werner,Ching C. Lau,Kirsten Sundby Hall,Hans Gelderblom,Paul A. Meyers,Richard Gorlick,Reinhard Windhager,Knut Helmke,Mikael Eriksson,Peter M. Hoogerbrugge,Paula J. Schomberg,Per-Ulf Tunn,Thomas Kühne,Heribert Jürgens,Henk van den Berg,Tom Böhling,Susan Picton,Marleen Renard,Peter Reichardt,Joachim Gerss,Trude Butterfass-Bahloul,Carol D. Morris,Pancras C.W. Hogendoorn,Beatrice Seddon,Gabriele Calaminus,Maria Michelagnoli,Catharina Dhooge,Matthew R. Sydes,Mark L. Bernstein +48 more
TL;DR: Investigation of maintenance therapy with pegylated interferon alfa-2b in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy found that MAP plus IFN-α-2B was not statistically different from MAP alone.
Journal ArticleDOI
Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
Michal Kovac,Claudia Blattmann,Sebastian Ribi,Jan Smida,Nikola S. Mueller,Florian Engert,Francesc Castro-Giner,Joachim Weischenfeldt,Monika Kovacova,Andreas H. Krieg,Dimosthenis Andreou,Per-Ulf Tunn,Hans Roland Dürr,Hans Rechl,Klaus-Dieter Schaser,Ingo Melcher,Stefan Burdach,Andreas E. Kulozik,Katja Specht,Karl Heinimann,Simone Fulda,Simone Fulda,Stefan S. Bielack,Gernot Jundt,Ian Tomlinson,Jan O. Korbel,Michaela Nathrath,Daniel Baumhoer +27 more
TL;DR: It is implied that multiple oncogenic pathways drive chromosomal instability during osteosarcoma evolution and result in the acquisition of BRCA-like traits, which could be therapeutically exploited.
Journal ArticleDOI
Recurrent PTPRB and PLCG1 mutations in angiosarcoma
Sam Behjati,Sam Behjati,Patrick S. Tarpey,Helen Sheldon,Inigo Martincorena,Peter Van Loo,Peter Van Loo,Gunes Gundem,David C. Wedge,Manasa Ramakrishna,Susanna L. Cooke,Nischalan Pillay,Nischalan Pillay,Hans Kristian Moen Vollan,Hans Kristian Moen Vollan,Hans Kristian Moen Vollan,Elli Papaemmanuil,Hans Koss,Hans Koss,Tom D. Bunney,Claire Hardy,Olivia Joseph,Sancha Martin,Laura Mudie,Adam Butler,Jon W. Teague,M Patil,Graham Steers,Yu Cao,Curtis Gumbs,Davis R. Ingram,Alexander J. Lazar,Latasha Little,Harshad S. Mahadeshwar,Alexei Protopopov,Ghadah A. Al Sannaa,Sahil Seth,Xingzhi Song,Jiabin Tang,Jianhua Zhang,Vinod Ravi,Keila E. Torres,Bhavisha Khatri,Dina Halai,Ioannis Roxanis,Daniel Baumhoer,Roberto Tirabosco,M Fernanda Amary,Chris Boshoff,Chris Boshoff,Ultan McDermott,Matilda Katan,Michael R. Stratton,P. Andrew Futreal,Adrienne M. Flanagan,Adrienne M. Flanagan,Adrian L. Harris,Adrian L. Harris,Peter J. Campbell,Peter J. Campbell +59 more
TL;DR: This work employed whole-genome, whole-exome and targeted sequencing to study the somatic changes underpinning primary and secondary angiosarcoma, and identified recurrent mutations in two genes, PTPRB and PLCG1, which are intimately linked to angiogenesis.